ICON plc’s Post

Many precision therapies benefit from the co-development of biomarkers with varying applications in clinical decision-making. However, oncology developers often face challenges integrating biomarkers into clinical trials. Read our whitepaper to learn how to de-risk biomarker selection and implementation. https://ow.ly/hSs750TFGLf

The Oncology Market Intelligence Package from DeciBio includes industry-leading reports on two key segments in the diagnostics market: liquid biopsy testing and clinical oncology biomarker testing. Insights in these reports can be used to anticipate shifts in the competitive landscape and identify emerging opportunities to inform pipeline strategies. The package also comes with 2 hours of DeciBio team time to answer any questions! Click here to purchase the Oncology Market Intelligence Package: https://lnkd.in/gfpSESxJ For any questions, feel free to contact Rebecca Burnham, PhD! #liquidbiopsy #marketinsights #oncology #biomarkers #marketreport

What treatment modalities are healthcare providers most excited about? What groundbreaking research is piquing their interest? Are antibody drug conjugates (ADCs) and theranostic—potentially transformative therapies getting the spotlight of late—living up to their hype? Join us for an engaging webinar that will unveil insights from oncologists surveyed at the ESMO 2024 conference. Our experts will explore the data that oncologists consider most impactful from the conference and examine the oncology drug development landscape, highlighting the surge in innovative trials and the strategic shifts in treatment approaches. Register here: https://lnkd.in/eEzFgcdu #SyneosHealth ft. Wouter Bartholomeus, Patrick Kelly, Dr. Prateet Minhas

Announcing Our "New Medicines, Novel Insights" Report: Revolutionizing Cancer Care I am thrilled to share our "New Medicines, Novel Insights" report, a significant step toward realizing the full potential of precision oncology. While many patients still face barriers to these life-changing treatments, our report offers hope and actionable strategies for better outcomes. Inside, you'll find: -Survivor Stories: Inspiring experiences with precision treatments. -Expert Insights: On clinical trials, regulatory strategies, and market access. -Actionable Steps: To accelerate precision cancer medicines to market. Join me in revolutionizing cancer care. Read the report here: Parexel #InternationalClinicalTrialsDay #CancerCare #Parexel #Withheart #Mycompany #Clinicaltrials #Oncology #PrecisionOncology #Puttingpatientsfirst

📣 If you would like to get all the take-aways from ESMO 2024, this webinar is definitively worth attending ! Register now 👇 #ESMO2024, #SyneosHealth, #oncology

Uncover new targets and biomarkers, deepen understanding of new treatments, accelerate clinical trials, and more, with the best-in-class, deepest multimodal dataset available for supporting discovery research and clinical development across oncology therapeutics and diagnostics.  Learn more: https://lnkd.in/eUQiytQf #OncologyResearch

In an ICON survey of oncology therapeutic developers 47% think that oncology drug development can be most improved through more consistent implementation of predictive biomarkers. Gain more insights into the oncology therapeutic landscape in our whitepaper. https://ow.ly/1q2c50Tu2gC #WorldCancerResearchDay

Announcing the development of multiple tutorials on how to define the Estimands in the Oncology trial design, paying attention to Statistical PLS, Formulas, Regulatory and Clinical features. This series will cover one of the most important segments in Designing Clinical Trials. The tutorials will be covering the following fields: -Immuno-oncology -Radio-oncology -Chemotherapy research -Combination therapy research -Neoadjuvant/Adjuvant treatment fields Estimand framework is extremely important in Oncology Clinical Trials and Oncology Pharma industry research in general. It is a part of Good Clinical Practice, some of the most important Regulatory documents such as ICH E9 (R1) and ICH M11. PS - will be adding the Data Science perspectives to the Estimand definitions #oncology #cancer #biostatistics #datascience #clinicaltrail #pharma #gcp #regulatory #stats #onco #estimand #tutorial

❓ How can multi-omics data revolutionize early biomarker discovery in oncology? Join Crown Bioscience’s webinar to explore how integrating multi-omics analysis with advanced patient models can de-risk drug candidates and increase clinical success rates. Learn how diverse oncology models help uncover precision medicine approaches and drug resistance mechanisms. Register now to unlock the potential of multi-omics in drug development: https://buff.ly/3OL251I #Oncology #Biomarkers #DrugDevelopment #PrecisionMedicine #Webinar #CrownBiosciences

What treatment modalities are healthcare providers most excited about? What groundbreaking research is piquing their interest? Are antibody drug conjugates and theranostics—potentially transformative therapies getting the spotlight of late—living up to their hype? This webinar unveils insights from oncologists surveyed at the ESMO 2024 conference, examines the oncology drug development landscape, and highlights the surge in innovative trials and the strategic shifts in treatment approaches. Watch the full recording: https://ow.ly/4Rgu30sHl2J #SyneosHealth